Pharmacogenomic Testing

Pharmacogenomic testing helps physicians select effective, safe medications and doses that are tailored to an individual’s specific genetic makeup. Physicians will receive a personalized report identifying individual genetic variants that may affect how a patient metabolizes a specific drug.

Is testing the right choice?

Adverse Drug Events (ADEs) are responsible for over 700,000 visits to the emergency room each year. Additionally, over 128,000 deaths in the US are directly attributable to ADEs, ranking as one of the top five causes of death in the US each year.

Up to ten per cent of the population aged 65 years and older suffers an ADE each year despite the proper administration of medications. Genetic variations affecting how drugs are metabolized are present in 75% of the population. Testing reduces the risk of ADEs caused by a dose that is too high, improves efficacy when a dose is too low, and enables selection of the right drug for the patient.

Pharmacogenomic Testing

Savings Attributed to PGx Testing

  • Costs of Adverse Drug Events estimated at $136 billion annually; costs said to exceed total cost of diabetic and cardiac care. Classen DC et al. JAMA 1997;277(4):301–306
  • Patients on genetically appropriate medications spent $5200 less than those on medications predicted to have a greater number of gene-drug interactions. J. Winner, Translational Psychiatry, Vol 3, 2013
  • Inpatient ADEs prolong hospital stays from 1.7 to 4.6 days. Office of Disease Prevention and Health Promotion
  • Outpatient ADEs result in over 107,000 hospital admissions annually. Adverse Drug Events in the Outpatient Setting: An 11 Year National Analysis Sep 2010
  • Patients with poor or ultra rapid CYP2D6 metabolizers face increased costs of between $4000 and $6000 annually. Journal of Clinical Psychopharmacology, 2000